ReviewLeukemia2010
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.
Review in Leukemia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 62 citations in OpenAlex.
- Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.Leukemia · 2013Trial
- Annexin-A1 Regulates Apoptosis-Autophagy Switch in a 5-FU-Resistant Colorectal Cancer Stem-Like Model Through the PI3K/AKT/mTOR Axis.Biochemical genetics · 2026Article
- BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP.Cell death & disease · 2023Article
- A Dual Level Analysis with Evolutionary Computing and Swarm Models for Classification of Leukemia.BioMed research international · 2022Article
- Sphingosine kinases are involved in the regulation of all-trans retinoic acid sensitivity of K562 chronic myeloid leukemia cells.Oncology letters · 2021Article
- Hedgehog Signaling and Truncated GLI1 in Cancer.Cells · 2020Review
- Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells.Iranian journal of basic medical sciences · 2019Review
- Leukemia multiclass assessment and classification from Microarray and RNA-seq technologies integration at gene expression level.PloS one · 2019Article
- Interaction of Abl Tyrosine Kinases with SOCS3 Impairs Its Suppressor Function in Tumorigenesis.Neoplasia (New York, N.Y.) · 2018Article
- Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.International journal of hematology · 2018Review
- Apoptosis induction in K562 human myelogenous leukaemia cells is connected to the modulation of Wnt/β-catenin signalling by BHX, a novel pyrazoline derivative.Cell proliferation · 2018Article
- Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.Molecular cancer · 2018Review
- Sustained mitogenic effect on K562 human chronic myelogenous leukemia cells by dietary lectin, jacalin.Glycoconjugate journal · 2016Article
- A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.Oncogene · 2015Article
- IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients.International journal of clinical and experimental medicine · 2014Article
- A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis.PloS one · 2014Article
- Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.OncoTargets and therapy · 2014Review
- CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells.Cancer cell international · 2013Article
- Molecular signatures of chronic myeloid leukemia stem cells.Biomarker research · 2013Article
- Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.Journal of the National Cancer Institute · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) is highly effective in controlling but not curing the disease. This is largely due to the inability of these kinase inhibitors to kill leukemia stem cells (LSCs) responsible for disease relapse. This stem cell resistance is not associated with the BCR-ABL kinase domain mutations resistant to kinase inhibitors. Development of curative therapies for CML requires the identification of crucial molecular pathways responsible for the survival and self-renewal of LSCs. In this review, we will discuss our current understanding of these crucial molecular pathways in LSCs and the available therapeutic strategies for targeting these stem cells in CML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.